Enanta files lawsuit against Pfizer antiviral drug Paxlovid
- Global Surge in Mycoplasma Pneumoniae Infections Sparks Expert Warnings
- Discovery of New Targets for Treating Cancer and Age-Related Diseases
- Why Blood Sugar Levels Increase in Winter?
- Zepbound: Eli Lilly new weight-loss drug 20% cheaper than Wegovy
- US$300K: Compensation Granted as Woman Dies Following COVID-19 Vaccination
- Gut Bacteria Enhance Cancer Immunotherapy: Study Reveals Potential Role of Lactobacillus reuteri
Enanta files lawsuit against Pfizer antiviral drug Paxlovid
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
- WHO Requests More Information from China on Pediatric Clustered Pneumonia
- First Chinese PD-1 Cancer Drug 30 Times More Expensive in U.S. than in China
- Cardiovascular Diseases Linked to COVID-19 Infections
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Enanta files lawsuit against Pfizer antiviral drug Paxlovid.
A few days ago, Enanta Pharmaceuticals formally filed a patent infringement lawsuit against Pfizer, alleging Pfizer’s alleged use of Enanta’s proprietary antiviral ingredients in the production of the COVID-19 antiviral drug Paxlovid.
In a lawsuit filed in the U.S. District Court for the District of Massachusetts, Delaware-based Enanta said it would seek a court acknowledgment of Pfizer’s infringement and ask Pfizer to pay damages, legal fees and other financial compensation measures.
Enanta pointed out that Pfizer’s antiviral 3CL protease inhibitor drug candidate used in the manufacturing design of Paxlovid is suspected of knowingly infringing Enanta’s patents, especially EDP-235, which Entanta has identified as a COVID-19 virus as early as early 2021. 19 lead compounds for R&D projects.
The main component of Pfizer’s COVID-19 antiviral drug Paxlovid, nirmatrelvir, is a SARS-CoV-23CL protease inhibitor.
Enanta began dosing its first human subject in a Phase I trial as early as February and was granted Fast Track designation by the U.S. Food and Drug Administration in March. Enanta filed a U.S. provisional patent application (‘048) back in July 2020, and the company then formally filed a utility patent application in July 2021, claiming priority.
In November 2021, the company refiled U.S. Patent Application No. 17/522,176 (‘176) to further support the priority claim filed in the earlier application.
After the U.S. Patent Office recognized Enanta’s patented innovation in June of that year, the company was officially granted the ‘953 patent, which Enanta has claimed in its latest court action is that Pfizer violated the patent.
“Pfizer allegedly used unlawful means to import Paxlovid products into the United States by actively inducing manufacture, use, sale, or offer for sale within the Commit and continue to engage in these infringing practices without permission or authorization.”
Enanta also specifically stated that it does not intend to ask Pfizer to immediately stop the distribution of Paxlovid or file a lawsuit in related matters, because the company recognizes the importance of Paxlovid to control the current epidemic.
However, Enanta stressed that Pfizer’s infringement has and will continue to damage Enanta’s legal rights, so Enanta is fully entitled to the corresponding damages.
Enanta is also currently seeking triple damages for Pfizer’s willful tort and other financial damages related to the issue.
So far, Pfizer has not responded to the matter.
Reference source:
Enanta Sues Pfizer For Patent Infringement in COVID-19 Antiviral Paxlovid
Enanta files lawsuit against Pfizer antiviral drug Paxlovid
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
